Objectives. The objective of this study was to assess the impact of unresected primary tumor, as well as extrahepatic metastasis, on the long-term prognosis of patients undergoing hepatic resection for non-functional neuroendocrine liver metastasis (NF-NELM). Methods. Patients who underwent hepatic resection for NF-NELM were identified from a multi-institutional database. Data on clinical and pathological details, as well as the long-term overall survival (OS) were obtained and compared. Propensity score matching was performed to generate matched pairs of patients. Results. Among the 332 patients with NF-NELM, 281 (84.6%) underwent primary tumor resection, while 51 (15.4%) did not. Patients who underwent primary resection were more likely to have a pancreatic primary and metachronous NELM. The long-term OS of patients who did and did not have the primary neuroendocrine tumor (NET) resected was comparable on both unmatched (10-year survival rate 66.8% vs. 54.0%, p = 0.192) and matched (10-year survival rate 75.7% vs. 60.4%, p = 0.271) analyses. In contrast, patients with NF-NELM and extrahepatic metastasis had a worse OS following resection compared with patients who had intrahepatic-only metastasis on unmatched (10-year survival rate 37.5% vs. 69.3%, p = 0.002) and matched (10-year survival rate 37.5% vs. 86.3%, p = 0.011) analyses. On multivariable analysis, while resection of the primary NET was not associated with OS (hazard ratio [HR] 0.7, 95% confidence interval [CI] 0.4-1.2, p = 0.195), the presence of extrahepatic metastasis was independently associated with long-term risk of death (HR 3.9, 95% CI 1.7-9.2, p = 0.002).
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Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are a heterogeneous group of rare tumors arising mainly from the pancreas and gastrointestinal tract. 1 While some GEP-NETs may have an indolent course, the liver is a common metastatic site for GEP-NETs. In fact, up to 60-90% of patients may develop synchronous or metachronous neuroendocrine liver metastasis (NELM) during the course of their disease.
Surgical resection is the main curative treatment option for patients with NELM. 2 Treatment goals for NELM often include both prolongation of survival and alleviation of tumor-related symptoms, which can include debilitating hormonal symptoms and mechanical symptoms. 3 While a subset of patients have functional tumors, a recent study of 9281 patients from the National Cancer Data Base with pancreatic NETs demonstrated that over 75% of NETs were non-functional. 4 Due to the lack of early symptoms, non-functional neuroendocrine tumors with liver metastasis (NF-NELM) are often discovered late, which can result in a higher incidence of the primary lesion being unresectable and/or the presence of extrahepatic metastasis. [4] [5] [6] NF-NETs are also more likely to be malignant and are often associated with worse outcomes versus functional NETs. [6] [7] [8] [9] Traditionally, the presence of unresectable primary disease and/or extrahepatic metastatic disease was considered advanced NELM. 10 While some investigators have recommended against resection of NELM in the setting of advanced disease, 11 other data have supported surgical debulking as a reasonable treatment of NELM that has yielded improved long-term survival. 12 As most patients with NELM die of liver failure due to intrahepatic tumor progression rather than the primary tumor or extrahepatic disease, liver resection may have a role, even in the setting of advanced disease. 12, 13 However, whether the presence of an unresectable primary tumor and/or extrahepatic metastatic disease should be considered a contraindication to liver resection for NF-NELM remains debated. As such, the objective of the current study was to define the impact of an unresected primary tumor and/or extrahepatic metastatic disease on the long-term prognosis of patients undergoing hepatic resection for NF-NELM.
METHODS

Study Cohort
A total of 548 patients who underwent liver-directed therapy for NELM from January 1980 to December 2015 were identified from nine international institutions. The Institutional Review Board of all participating institutions approved the study. The diagnoses of all NELM patients were confirmed histologically. Patients with hormonally functional NETs (n = 201), receipt of liver ablation only (n = 11), and patients who died within 30 days after surgery (n = 4) were excluded.
Data Collection and Follow-Up
Data on clinical, operative, and pathological details were collected for each patient at each institution in a standardized database pertaining to both the primary tumor and liver metastases. Extrahepatic metastatic disease was determined by imaging studies, e.g. computed tomography (CT) scan, octreoscan, positron emission tomography (PET)-CT, etc., and/or biopsy before surgery among the different centers. Grade of tumor differentiation was classified as well (G0), moderate (G1), or poor (G3) according to the 2010 WHO grading system. 14 An R0 resection was defined as the absence of macroscopic or microscopic disease at the surgical margin, while an R1 resection was defined as the microscopic presence of tumor and R2 was classified as macroscopic presence of tumor. 15 
Statistical Analysis
Continuous variables were expressed as medians with interquartile ranges (IQRs), while categorical variables were reported as totals and frequencies. Univariable comparisons were assessed by using the Mann-Whitney U test, Chi square test, or Fisher exact test, as appropriate. Survival was evaluated using Kaplan-Meier curves and median values were compared using the log-rank tests. The impact of various clinicopathological factors on overall survival (OS) was assessed using a Cox proportional hazards model and expressed as hazard ratio (HR) and 95% confidence interval (CI). Factors with a p value \ 0.05 by univariate analysis were included in the multivariate analysis. Propensity score matching (PSM) was used to adjust for differences in baseline characteristics between groups. In all analyses, a p value \ 0.05 (two-tailed) was considered statistically significant. Statistical analyses were performed using SPSS 22.0 (IBM Corporation, Armonk, NY, USA).
RESULTS
Demographic and Clinicopathological Characteristics
Among the 548 patients diagnosed with GEP-NETs, a total of 332 (60.6%) patients who underwent hepatectomy for NF-NELM were included in the analytic cohort (Table 1) . Median patient age was 58 years (IQR 49-67) and nearly half of patients were female (n = 151, 45.5%). Among all patients, 187 (56.3%) presented with nonspecific clinical symptoms, including abdominal cramping. Primary tumor site included the pancreas (n = 149, 44.9%), gastrointestinal tract (n = 129, 38.8%), tracheobronchial and lung (n = 14, 4.2%), and unknown location (n = 40, 12%). Liver metastases were synchronous in 217 (65.4%) patients and metachronous in 115 (34.6%) patients. Bilateral liver disease was present in the majority of patients (n = 181, 54.5%) and most patients had an estimated C 50% liver involvement (n = 440, 79.4%). Extrahepatic metastatic disease was noted in 37 (11.1%) patients at the time of liver surgery. Most patients (n = 283, 85.2%) did not receive any additional treatment before hepatectomy, while 22 (6.6%) and 27 (8.1%) patients had received octreotide or chemotherapy, respectively. Most patients (n = 205, 61.7%) underwent a parenchymal-sparing resection. During the operation, tumor ablation was concomitantly performed in 76 (22.9%) patients. On final pathology, 291 (87.7%) patients had a curative-intent resection (R0/R1), while 41 (12.3%) patients had a macroscopically positive (R2) surgical margin. The majority of patients (n = 203, 61.1%) did not receive any adjuvant treatment, whereas 129 (38.9%) patients received postoperative octreotide or chemotherapy.
Overall Survival (OS): Primary Resected Versus Unresected Non-functional Neuroendocrine Liver Metastasis (NF-NELM)
Among the 332 patients with NF-NELM, the primary tumor was resected in 281 (84.6%) patients; 51 (15.4%) patients had an unresected primary tumor at the time of liver surgery for NELM (Fig. 1) . The 1-, 3-, 5-, and 10-year survival of the entire cohort was 97.4, 89.5, 82.2, and 65.1%, respectively. Patients who had a resected primary 
OS: Presence of Extrahepatic Metastatic Disease Versus Intrahepatic-Only Metastasis
At the time of NF-NELM resection, extrahepatic metastatic disease was noted in 37 (11.1%) patients (Fig. 1) . Extrahepatic sites included the lungs (n = 11), peritoneum (n = 19), bone (n = 7), and other sites (n = 12); 9 patients had multiple sites of extrahepatic metastases. Compared with patients who had intrahepatic-only disease, patients with NF-NELM plus extrahepatic metastasis were more likely to have a pancreatic primary tumor (47.5% vs. 24.3%, p = 0.008) [Electronic Supplementary Table 2] . Patients with extrahepatic metastatic disease had a worse OS versus patients with intrahepatic-only metastasis (10-year survival rate, 69.3% vs. 37.5%, p = 0.002) [ Fig. 3a ]. After 1:2 PSM, the analytic cohort included 95 patients who had comparable demographic and clinicopathologic characteristics (Electronic Supplementary Table 2 ). In the matched cohort, the presence of extrahepatic metastatic disease remained associated with worse long-term outcome (10-year survival, extrahepatic metastatic disease 36.3% vs. intrahepatic-only disease 77.9%, p = 0.019) [Fig. 3b ].
Risk Factors Associated with OS of NF-NELM
On univariate analysis, symptomatic, pancreatic primary NET, synchronous liver metastasis, R2 resection, tumor grade, and extrahepatic metastatic disease were each associated with worse long-term survival among patients with NF-NELM ( Table 2) . Of note, resection of the primary NET was not associated with OS (HR 0.7, 95% CI 0.4-1.2, p = 0.195). On multivariable analysis, after taking into account all potential confounding factors, the presence of extrahepatic metastatic disease (HR 3.9, 95% CI 1.7-9.2, p = 0.002) remained independently associated with worse outcome among patients with NF-NELM.
DISCUSSION
With improvements in abdominal imaging, the incidence of NF-NETs has increased to 50-75% of all GEPNETs. 16 In fact, over half of NF-NET patients are asymptomatic and have disease sporadically discovered on imaging for an unrelated problem. 14, 17, 18 Due to occult progression and delayed diagnosis, more NF-NET patients may present with an unresectable primary tumor and extrahepatic metastasis than patients with functional NETs. 14, 17, 18 In turn, the presence of unresectable primary NETs and/or extrahepatic metastasis are still considered a contraindication to surgery by many clinicians. 11, 19 However, aggressive onco-surgery has been increasingly advocated, even in the presence of advanced metastatic disease. 20, 21 The current study was important as it specifically defined the outcomes of patients with advanced NF-NELM who had unresected primary NETs, as well as extrahepatic metastasis using a large, international, multiinstitutional database. Of note, long-term survival was comparable among patients who had the primary NET resected versus patients who had an unresectable primary NET left in situ. Comparable long-term OS among patients who did and did not have the primary NET resected was noted on both unadjusted (10-year survival rate 66.8% vs. 54.0%, p = 0.192) and adjusted (10-year survival rate 75.7% vs. 60.4%, p = 0.271) analyses. In contrast, the presence of extrahepatic metastatic disease was strongly associated with a worse OS compared with intrahepaticonly disease as patients who had extrahepatic metastatic disease were noted to have a 2.5-fold higher risk of death long-term.
The beneficial role of resecting the primary NET has been a topic of debate. Givi et al. reported on 84 patients with gastrointestinal carcinoid hepatic metastases and noted that primary tumor resection was associated with improved survival. 22 However, all patients in this study received non-surgical treatment for NELM. 22 Whether there is a role for surgical resection of NF-NELM in the setting of an unresected primary NET remains largely unknown. Importantly, data from the current study demonstrated comparable long-term survival among patients who did and did not have the primary NET resected. In fact, the presence of an unresected primary NET was not a risk factor for OS among patients undergoing resection of NF-NELM. As such, hepatic resection of NF-NELM should be strongly considered, even in the setting of an unresectable primary NET tumor.
According to the European Neuroendocrine Tumor (ENET) system, as well as other investigators, the presence of extrahepatic metastatic disease is a strong negative prognostic factor and should be considered a relative contraindication to surgery among patients with NELM. 8, 9, 23, 24 In the current study, patients with extrahepatic metastasis who underwent resection of NELM had a more than twofold increased risk of death long-term.
Interestingly, the 10-year survival of patients with extrahepatic NET disease who underwent resection of NELM was still almost 40%. Whether patients with non-functional NET who have extrahepatic metastatic disease and extensive NELM benefit from surgery is controversial. Mayo et al. reported on patients with NELM who were treated with surgery versus intra-arterial therapy (IAT) and noted an overall improved survival with surgery 23 However, among patients who had an NF-NET and large ([ 50%) liver involvement, there was no difference in survival among patients who underwent resection versus IAT. 23 Similarly, Kennedy et al. reported the benefit of Y-90 microsphere therapy in the treatment of patients with advanced NETs. 25 Overall, the presence of extrahepatic metastatic disease has been reported to have a varied effect on long-term prognosis relative to the extent of liver disease. 12, 13, 26, 27 In one study using the Surveillance, Epidemiology, and End Results (SEER) database, Franko et al. examined patients with non-functional PNETs and reported that while distant metastasis was a negative prognostic marker, surgical resection improved the long- term outcome of patients with distal metastasis versus nonsurgical treatments. 6 However, given the limitations of the SEER dataset, this study had no clear classification of what constituted a 'true' distant metastasis. 6 Collectively, the data would suggest that hepatic resection of NF-NELM may be reasonable in the presence of low-volume extrahepatic disease. 8, 28 However, given the higher risk of poor long-term outcomes defined in the current study, patients with a large burden of intra-and extrahepatic disease may not derive a strong benefit from surgery, and less invasive therapeutic approaches such as IAT should be considered.
The current study had several limitations. The multi-institutional nature of the cohort allowed for an increased sample size to examine a relatively rare disease, yet selection criteria for surgery among different centers may have been inconsistent, and the heterogeneity of the patient population may have allowed for certain biases. In addition, only patients who underwent hepatic resection for NF-NELM were included in the current database; therefore, 'control' patients who were untreated or received non-surgical treatment were not available for comparison purposes. As such, the survival benefit of resection versus nonsurgical treatments among patients with presence of primary unresected or extrahepatic metastatic disease might be limited in the current study, which needs to be further evaluated.
CONCLUSIONS
At the time of surgical treatment for NF-NELM, approximately 1 of 7 and 1 of 10 patients presented with an unresectable primary tumor and/or extrahepatic disease, respectively. Patients with primary unresected NET had a comparable survival versus patients who had the primary NET resected. In contrast, survival among patients with extrahepatic metastatic disease was worse versus patients who had intrahepatic-only disease. While surgery should be considered for patients with NF-NELM who have an unresectable primary tumor, operative resection of NF-NELM may not be as beneficial in patients with extrahepatic disease.
